The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Controlled Trial of Interleukin-2 Infusions in Patients Infected with the Human Immunodeficiency Virus
Open accessAbstract
BACKGROUND: Interleukin-2 is a cytokine that regulates the proliferation and differentiation of lymphocytes. In preliminary studies, intermittent infusions of interleukin-2 led to increases in CD4 counts in patients with human immunodeficiency virus (HIV) infection and more than 200 CD4 cells per cubic millimeter. We conducted a controlled study to evaluate the long-term effects of such therapy on both CD4 counts and the viral burden. METHODS: Sixty HIV-infected patients with base-line CD4 counts above 200 cells per cubic millimeter were randomly assigned to receive either interleukin-2 plus antiretroviral therapy (31 patients, 1 of whom was lost to follow-up) or antiretroviral therapy alone (29 patients). Interleukin-2 was administered every two months for six cycles of five days each, starting at a dosage of 18 million i.u. per day. Safety and immunologic and virologic measures were monitored monthly until four months after the last treatment cycle. RESULTS: In patients treated with interleukin-2, the mean (+/-SE) CD4 count increased from 428 +/- 25 cells per cubic millimeter at base line to 916 +/- 128 at month 12, whereas in the control group, the mean CD4 count decreased from 406 +/- 29 cells per cubic millimeter to 349 +/- 41 (P < 0.001). There were no significant differences between the groups in serial measurements of the plasma HIV RNA or p24 antigen concentration during the 12 months of treatment. Constitutional symptoms (fever, malaise, and fatigue) and asymptomatic hyperbilirubinemia were the chief dose-limiting toxic effects of interleukin-2 therapy. CONCLUSIONS: In patients with HIV infection and base-line CD4 counts above 200 cells per cubic millimeter, intermittent infusions of interleukin-2 produced substantial and sustained increases in CD4 counts with no associated increase in plasma HIV RNA levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of serial measurements in medical research.
Matthews, J. N., Altman, D. G., Campbell, M. J., & Royston, P. (1990) · BMJ · doi:10.1136/bmj.300.6719.230 · Cited by 3,136
Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma
Mellors, J. W., Rinaldo, C. R., Gupta, P., White, R. M., Todd, J. A., & Kingsley, L. A. (1996) · Science · doi:10.1126/science.272.5265.1167 · Cited by 2,660
Interleukin-2: Inception, Impact, and Implications
Smith, K. A. (1988) · Science · doi:10.1126/science.3131876 · Cited by 2,153
In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
Condra, J. H., Schleif, W. A., Blahy, O. M., Gabryelski, L. J., Graham, D. J., Quintero, J., Rhodes, A., Robbins, H. L., Roth, E., Shivaprakash, M., et al. (1995) · Nature · doi:10.1038/374569a0 · Cited by 974
Quantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion
Mellors, J. W., Kingsley, L. A., Rinaldo, C. R., Todd, J. A., Hoo, B. S., Kokka, R. P., & Gupta, P. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-8-199504150-00003 · Cited by 917
De, N., Rs, K., Rl, L., Chrismon, J. H., Merritt, R., Da, A., & Giovino, G. A. (1994) · PubMed · Cited by 797
Phair, J., Muñoz, A., Detels, R., Kaslow, R., Rinaldo, C., Saah, A., & the Multicenter AIDS Cohort Study Group* (1990) · New England Journal of Medicine · doi:10.1056/nejm199001183220304 · Cited by 684
Danner, S. A., Carr, A., Leonard, J. M., Lehman, L. M., Gudiol, F., Gonzales, J., Raventos, A., Rubio, R., Bouza, E., Pintado, V., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512073332303 · Cited by 567
CD4 Counts as Predictors of Opportunistic Pneumonias in Human Immunodeficiency Virus (HIV) Infection
Masur, H., Ognibene, F. P., Yarchoan, R., Shelhamer, J. H., Baird, B. F., Travis, W., Suffredini, A. F., Deyton, L., Kovacs, J. A., Falloon, J., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-3-223 · Cited by 500
Self-citationA Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 Infection
Markowitz, M., Saag, M., Powderly, W. G., Hurley, A. M., Hsu, A., Valdes, J. M., Henry, D., Sattler, F., Marca, A. L., Leonard, J. M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512073332204 · Cited by 493
Cited by
Type 1/Type 2 Immunity in Infectious Diseases
Spellberg, B., & Edwards, J. E. (2001) · Clinical Infectious Diseases · doi:10.1086/317537 · Cited by 911
Tolerance, not immunity, crucially depends on IL-2
Malek, T. R., & Bayer, A. L. (2004) · Nature Reviews Immunology · doi:10.1038/nri1435 · Cited by 820
Immune activation and inflammation in HIV‐1 infection: causes and consequences
Appay, V, & Sauce, D. (2008) · The Journal of Pathology · doi:10.1002/path.2276 · Cited by 743
CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions
Hashimoto, M., Kamphorst, A. O., Im, S. J., Kissick, H. T., Pillai, R. N., Ramalingam, S. S., Araki, K., & Ahmed, R. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-012017-043208 · Cited by 656
Connors, M., Kovacs, J. A., Krevat, S., Gea-Banacloche, J. C., Sneller, M. C., Flanigan, M., Metcalf, J. A., Walker, R. E., Falloon, J., Baseler, M., et al. (1997) · Nature Medicine · doi:10.1038/nm0597-533 · Cited by 515
Self-citation
Metadata
- Authors
- Kovacs, J. A., Vogel, S., Albert, J. M., Falloon, J., Davey, R. T., Walker, R. E., Polis, M. A., Spooner, K., Metcalf, J. A., Baseler, M., Fyfe, G., Lane, H. C., Dewar, R. J., & Masur, H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1996-10-31
- Volume
- 335
- Issue
- 18
- Pages
- 1350-1356
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2013068560
- Cited by
- 402
- References
- 14
- FWCI
- 9.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Controlled Trial of Interleukin-2 Infusions in Patients Infected with the Human Immunodeficiency Virus. https://app.cochat.ai/papers/10.1056/nejm199610313351803
- The paper
- Kovacs, J. A., Vogel, S., Albert, J. M., Falloon, J., Davey, R. T., Walker, R. E., Polis, M. A., Spooner, K., Metcalf, J. A., Baseler, M., Fyfe, G., Lane, H. C., Dewar, R. J., & Masur, H. (1996). Controlled Trial of Interleukin-2 Infusions in Patients Infected with the Human Immunodeficiency Virus. New England Journal of Medicine. https://doi.org/10.1056/nejm199610313351803
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.